Colorectal cancer

Lancet Digital Health Study Confirms MAGENTIQ-COLO™ AI-aided Colonoscopy Technology Improves Adenoma Detection Rates

Retrieved on: 
Thursday, February 22, 2024

HAIFA, Israel, Feb. 22, 2024 /PRNewswire/ -- MAGENTIQ-EYE LTD., an Israeli based technology company founded in 2014, announced today that a comprehensive study on the performance of MAGENTIQ-COLO™ CADe version has been published in the prestigious Lancet Digital Health medical journal.

Key Points: 
  • The research validates that MAGENTIQ-COLO is at the highest level of performance in the AI-aided colonoscopy category.
  • The study shows that using MAGENTIQ-COLO™ increases adenoma detection rate (ADR) by 7% in absolute values.
  • In addition to ADR, the study also measured MAGENTIQ-COLO's impact on adenoma miss rate (AMR), and showed that with MAGENTIQ-COLO, AMR was 17% lower in absolute values.
  • "We are honored to be published by Lancet Digital Health, a journal with a phenomenal worldwide reputation for circulating innovative, practice-changing research," said Dror Zur, Founder & CEO, MAGENTIQ EYE.

EQS-News: Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Retrieved on: 
Thursday, March 7, 2024

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Key Points: 
  • Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
    BERKELEY, US – MAINZ, Germany – February 27th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its participation as an exhibitor at the esteemed Gynecology Congress (‘Gynäkologie und Geburtshilfe aktuell’) in Stuttgart, Germany, on March 1st.
  • The Gynecology Congress is a premier event dedicated to gynecological health, offering Mainz Biomed an invaluable opportunity to connect with these vital healthcare providers.
  • In the coming months, Mainz Biomed will continue to actively participate in medical conferences that cater to its key demographic.

Gut microbiome: meet Bilophila wadsworthia – a microbe that’s both friend and foe

Retrieved on: 
Friday, February 16, 2024

Hydrogen sulfide is the gas responsible for the rotten-egg odour that you come across near stagnant water and in drains.

Key Points: 
  • Hydrogen sulfide is the gas responsible for the rotten-egg odour that you come across near stagnant water and in drains.
  • Bilophila wadsworthia is one such species of these bacteria.
  • The bacteria that break down sulfur-containing organic matter and produce hydrogen sulfide are fittingly called sulfate-reducing bacteria.
  • Sulfate-reducing bacteria are an important part of the normal human gut microbiome, and small amounts of hydrogen sulfide are required in the human gut environment.
  • Bilophila wadsworthia was discovered in the 1980s, when it was found in people who had severe appendicitis.
  • The researchers found that it grew really well in bile, which is why the genus name is Bilophila (meaning bile loving).
  • Since then, research has associated Bilophila wadsworthia with negative effects in the gut.
  • It’s not clear how or why expansion of Bilophila wadsworthia can occur in the gut.


Jade Davies receives funding from UKRI via the BBSRC as part of the Norwich Research Park Doctoral Training Partnership (grant no. BB/M011216/1).

iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology

Retrieved on: 
Thursday, February 15, 2024

BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that New Drug Part has secured a potent anti-cancer candidate, PHAGERIA®, with broad antimicrobial activity against ETBF (Enterotoxigenic B. fragilis), a harmful microbe associated with colorectal cancer.

Key Points: 
  • iNtRON stated that following the proprietary development of the Robot Bacteriophage 2nd generation technology, additional in-vitro evolution technology was applied.
  • The Company previously secured the technology to customize and edit bacteriophage genomes as desired using tailored CRISPR/Cas technology and Random Transposon Mutagenesis in 2022.
  • Recently, the Company has advanced this technology further to develop a more potent anti-cancer candidate, PHAGERIA®.
  • This achievement is significant as it is the first instance of applying in-vitro Evolution technology to ETBF bacteriophages, demonstrating the excellence of the bacteriophage gene editing technology (CRISPR/Cas) and Robotic Bacteriophage improvement platform technology of the Company.

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

Retrieved on: 
Wednesday, February 14, 2024

SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced two clinical trial collaboration and supply agreements (CTCSAs) with Novartis (NYSE: NVS) for the MEK inhibitor trametinib (MEKINIST®).

Key Points: 
  • Erasca is sponsoring the trials, and Novartis is supplying trametinib at no cost.
  • “Both trials are supported by compelling anti-tumor activity with a tolerable and manageable adverse event profile demonstrated in clinical data generated by Novartis.
  • Both RAS Q61X solid tumors and NRASm melanoma represent high unmet needs with no approved targeted therapies for these respective mutation types.
  • Erasca is exploring whether naporafenib in combination with trametinib can improve outcomes and help provide meaningful therapeutic benefit for these advanced solid tumor indications.

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

Retrieved on: 
Tuesday, February 13, 2024

As of December 31, 2023, MEI had $59.5 million in cash, cash equivalents, and short-term investments with no outstanding debt.

Key Points: 
  • As of December 31, 2023, MEI had $59.5 million in cash, cash equivalents, and short-term investments with no outstanding debt.
  • Research and development expenses decreased by $11.4 million to $3.9 million for the quarter ended December 31, 2023, compared to $15.3 million for the quarter ended December 31, 2022.
  • General and administrative expenses decreased by $0.5 million to $8.0 million for the quarter ended December 31, 2023, compared to $8.5 million for the quarter ended December 31, 2022.
  • MEI recognized no revenue for the quarter ended December 31, 2023, compared to $32.7 million for the quarter ended December 31, 2022.

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Retrieved on: 
Friday, February 9, 2024

SAN DIEGO and SUZHOU, China, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced progress and expansion of the clinical collaboration development program for its masked, anti-CTLA-4 SAFEbody, ADG126 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC).

Key Points: 
  • Given the safety profile of ADG126, Adagene has also initiated evaluation of 20 mg/kg loading doses in combination with pembrolizumab in patients with advanced/metastatic cancer.
  • The company plans dose expansion with this regimen in patients with MSS CRC in the US and Asia Pacific.
  • Adagene has also received clearance from the CDE in China to initiate clinical evaluation of ADG126 in combination with pembrolizumab.
  • Data from the ongoing phase 1b/2 clinical trial of ADG126 in combination with pembrolizumab, including dose expansion cohorts, are anticipated throughout 2024:
    Evaluation of 20 mg/kg loading doses for Project Optimus requirements:

Oncology Molecular Diagnostics Market Research Report 2023: Transformative Technologies to Revolutionize Cancer Care - Global Outlook and Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 7, 2024

The "Oncology Molecular Diagnostics Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oncology Molecular Diagnostics Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global healthcare landscape is poised to witness significant growth in the oncology molecular diagnostics market, with projections indicating a powerful Compound Annual Growth Rate (CAGR) of 14.81% from 2022 to 2028.
  • New research findings highlight the transformative impact of advanced diagnostic tools on the precision of cancer care, thereby driving this unprecedented market expansion.
  • The pivotal role of companion diagnostics in oncology drug development emerges as a key trend, where individualized patient care takes precedence.

Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting

Retrieved on: 
Wednesday, February 7, 2024

in 2024, we are excited to share our latest development status.

Key Points: 
  • in 2024, we are excited to share our latest development status.
  • A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Angeles in the United States.
  • Subsequently, the concentration of DFP-10917, the active component of DFP-14927, delivering into cancer tissue in patients treated with DFP-14927 is being measured to confirm PK/PD relationship for the clinical efficacy of DFP-14927.
  • On 6th Feb. 2024, we are pleased to announce that we have submitted an abstract to the 2024 ASCO annual meeting to be held from May 31st this year in Chicago.

King Charles is having cancer treatment. What can he, and others with cancer, expect?

Retrieved on: 
Wednesday, February 7, 2024

The type of cancer has not been revealed, but it has been confirmed it is not prostate cancer.

Key Points: 
  • The type of cancer has not been revealed, but it has been confirmed it is not prostate cancer.
  • So what can King Charles and the millions of others who are newly diagnosed with cancer each year expect?

What actually is cancer?

  • Normally, cells multiply and die in a regulated way, so each new cell replaces a cell that is lost.
  • The cancer cells can break away and travel through the bloodstream or lymph vessels to other parts of the body.
  • If the primary cancer cells grow and form another tumour at a new site, it is called a secondary cancer or metastasis.


Read more:
How does cancer spread to other parts of the body?

Millions of new cases each year

  • And King Charles’ diagnosis is one of roughly 19.3 million new cases of cancer diagnosed worldwide each year.
  • The most common cancers can vary between countries, due to a number of factors such as genetics, lifestyle and environment.
  • In Australia, for example, the most common cancers are prostate, breast, skin melanoma, colorectal cancer and lung cancer.

Cancer accounts for 1 in 6 deaths

  • Worldwide, leading cancer-related deaths are from lung, colorectal, stomach, breast, pancreatic, oesophageal, prostate and liver cancer.
  • In 2023, there were roughly 165,000 cases of cancer diagnosed and 51,000 cancer deaths in Australia.

But more people are surviving cancer

  • Advances in medicine and treatments for cancer have led to more people surviving cancer.
  • This therapy destroys cancer cells using a controlled dose of radiation to kill or damage cancer cells so they cannot grow, multiply or spread, while sparing surrounding healthy tissue.
  • There is also “CAR T-cell therapy”, which harnesses the body’s own immune system to fight against cancer.
  • Thanks to COVID, mRNA technology and other nanoparticle delivery systems are also an area yielding promising results for cancer vaccines.

Do treatments work?

  • With such new treatments, cancer survival rates have improved significantly.
  • In Australia, for example, five-year survival rates improved from 52% to 70% from 1989–1993 to 2014–2018.

In a nutshell


King Charles’ cancer diagnosis, at the age of 75, is one of millions of new cancer diagnoses globally. While cancer remains a leading cause of death worldwide, survival rates are improving thanks to extensive advances in treatments and treatment options.

Read more:
What happens if King Charles can no longer perform his duties?


Sathana Dushyanthen does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.